Nateglinide
As of the edition of 20 October 2026, Nateglinide is a small molecule: marketed, first approved in 2000 (US); acts on ABCC8 and KCNJ11; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2000
- Kind
- Small molecule
- Brand name
- Starlix
- First approved
- 22 December 2000 (US)
- Approvals on record
- 4 in 2 regions
- Holder of the most recent approval
- Novartis; 3 holders in all
- Withdrawn from market
- 20 November 2008 (in some regions)
- Registered trials
- 15, 0 stopped early
- Disease areas
- Nutrition and metabolism; Hormones
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Companies that need a new molecule because of this drug
2 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product2 company-target rows are on route B because of Nateglinide.
See the 2 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 3 | 3 | 0 | 0 |
| Phase 3 | 3 | 3 | 0 | 0 |
| Phase 4 | 9 | 9 | 0 | 0 |
| All trials | 15 |